

# Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/C5D66DEF356EN.html>

Date: October 2021

Pages: 45

Price: US\$ 125.00 (Single User License)

ID: C5D66DEF356EN

## Abstracts

Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Cyclopharm Ltd (Cyclopharm) is a radiopharmaceutical company that manufactures medical and healthcare equipment and components in the nuclear medicine. The company's products include Technegas, an ultra-fine dispersion of technetium-labelled carbon used for detection of pulmonary embolism. The company is evaluating Technegas in new indications including chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary hypertension, lung volume reduction and Asthma. Cyclopharm operates a joint venture, Macquarie Medical Imaging, which provides diagnostic imaging services such as magnetic resonance imaging (MRI), computed tomography (CT), breast imaging, X-ray, ultrasound, dual-energy X-ray absorptiometry (DEXA) and positron emission tomography (PET) scanning. The company harnesses its Ultralute technology, which extends the life of Molybdenum-99 generators. It operates in Asia Pacific, Canada, Latin America, Europe and Germany. Cyclopharm is headquartered in New South Wales, Australia.

### Cyclopharm Ltd Key Recent Developments

Aug 23,2021: Cyclopharm : Half year 2021 results – Revenues rebound

Feb 25,2021: Cyclopharm: Financial year 2020 results

Feb 05,2021: CYC receives 2020 R&D tax incentive - \$3.1 million

Jul 07,2020: Cyclopharm: 1H 2020 business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Cyclopharm Ltd - Key Facts  
Cyclopharm Ltd - Key Employees  
Cyclopharm Ltd - Key Employee Biographies  
Cyclopharm Ltd - Major Products and Services  
Cyclopharm Ltd - History  
Cyclopharm Ltd - Company Statement  
Cyclopharm Ltd - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries  
Joint Venture

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Cyclopharm Ltd - Business Description  
Business Segment: Molecular Imaging  
Overview  
Performance  
Business Segment: Technegas  
Overview  
Performance  
Geographical Segment: Asia Pacific  
Performance  
Geographical Segment: Canada  
Performance  
Geographical Segment: Europe  
Performance  
Geographical Segment: Other  
Performance  
R&D Overview  
Cyclopharm Ltd - Corporate Strategy  
Cyclopharm Ltd - SWOT Analysis  
SWOT Analysis - Overview  
Cyclopharm Ltd - Strengths  
Cyclopharm Ltd - Weaknesses

Cyclopharm Ltd - Opportunities  
Cyclopharm Ltd - Threats  
Cyclopharm Ltd - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Cyclopharm Ltd, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Aug 23, 2021: Cyclopharm : Half year 2021 results – Revenues rebound  
Feb 25, 2021: Cyclopharm: Financial year 2020 results  
Feb 05, 2021: CYC receives 2020 R&D tax incentive - \$3.1 million  
Jul 07, 2020: Cyclopharm: 1H 2020 business update

### **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Cyclopharm Ltd, Key Facts  
Cyclopharm Ltd, Key Employees  
Cyclopharm Ltd, Key Employee Biographies  
Cyclopharm Ltd, Major Products and Services  
Cyclopharm Ltd, History  
Cyclopharm Ltd, Subsidiaries  
Cyclopharm Ltd, Joint Venture  
Cyclopharm Ltd, Key Competitors  
Cyclopharm Ltd, Ratios based on current share price  
Cyclopharm Ltd, Annual Ratios  
Cyclopharm Ltd, Annual Ratios (Cont...1)  
Cyclopharm Ltd, Annual Ratios (Cont...2)  
Cyclopharm Ltd, Interim Ratios  
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Cyclopharm Ltd, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Cyclopharm Ltd, Performance Chart (2016 - 2020)

Cyclopharm Ltd, Ratio Charts

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Cyclopharm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Cyclopharm Ltd (CYC) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/C5D66DEF356EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5D66DEF356EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970